Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by Stanley Muller on May 13th, 2026

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.00.

Several research firms have weighed in on COYA. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, March 23rd.

Get Our Latest Stock Analysis on COYA

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC boosted its holdings in Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Coya Therapeutics in the second quarter valued at about $119,000. JPMorgan Chase & Co. purchased a new stake in shares of Coya Therapeutics in the third quarter valued at about $28,000. CM Management LLC lifted its position in shares of Coya Therapeutics by 50.0% during the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Dauntless Investment Group LLC lifted its position in shares of Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Stock Performance

COYA stock opened at $4.29 on Wednesday. The stock’s 50 day simple moving average is $4.37 and its 200 day simple moving average is $5.06. The company has a market cap of $100.64 million, a P/E ratio of -3.38 and a beta of 0.55. Coya Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $7.75.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.15 million. Equities analysts predict that Coya Therapeutics will post -1.81 earnings per share for the current year.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.